1
|
Tonnis K, Kasting GB, Jaworska J. Impact of solvent dry down, phase change, vehicle pH and slowly reversible keratin binding on skin penetration of cosmetic relevant compounds: II. Solids. Int J Pharm 2024; 661:124451. [PMID: 38992735 DOI: 10.1016/j.ijpharm.2024.124451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Revised: 06/11/2024] [Accepted: 07/07/2024] [Indexed: 07/13/2024]
Abstract
We extended a mechanistic, physics-based framework of the dry down process, previously developed for liquids and electrolytes, to solids and coded it into the latest UB/UC/P&G skin permeation model, herein renamed DigiSkin. The framework accounts for the phase change of the permeant from dissolved in a solvent (liquid) to precipitated on the skin surface (solid). The evaporation rate for the solid is reduced due to lower vapor pressure for the solid state versus subcooled liquid. These vapor pressures may differ by two orders of magnitude. The solid may gradually redissolve and penetrate the skin. The framework was tested by simulating the in vitro human skin permeation of the 38 cosmetically relevant solid compounds reported by Hewitt et al., J. Appl. Toxicol. 2019, 1-13. The more detailed handling of the evaporation process greatly improved DigiSkin evaporation predictions (r2 = 0.89). Further, we developed a model reliability prediction score classification using diverse protein reactivity data and identified that 15 of 38 compounds are out of model scope. Dermal delivery predictions for the remaining chemicals have excellent agreement with experimental data. The analysis highlighted the sensitivity of water solubility and equilibrium vapor pressure values on the DigiSkin predictions outcomes influencing agreement with the experimental observations.
Collapse
Affiliation(s)
- Kevin Tonnis
- College of Engineering and Applied Science, The University of Cincinnati, Cincinnati, OH 45221, USA
| | - Gerald B Kasting
- The James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45267-0514, USA
| | - Joanna Jaworska
- The Procter & Gamble Company, Discovery Innovation Platforms, Brussels Innovation Center, Belgium.
| |
Collapse
|
2
|
Dallmann A, Teutonico D, Schaller S, Burghaus R, Frechen S. In-Depth Analysis of the Selection of PBPK Modeling Tools: Bibliometric and Social Network Analysis of the Open Systems Pharmacology Community. J Clin Pharmacol 2024. [PMID: 38708848 DOI: 10.1002/jcph.2453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Accepted: 04/09/2024] [Indexed: 05/07/2024]
Abstract
Since the Open Source Initiative laid the foundation for the open source software environment in 1998, the popularity of free and open source software has been steadily increasing. Model-informed drug discovery and development (MID3), a key component of pharmaceutical research and development, heavily makes use of computational models which can be developed using various software including the Open Systems Pharmacology (OSP) software (PK-Sim/MoBi), a free and open source software tool for physiologically based pharmacokinetic (PBPK) modeling. In this study, we aimed to investigate the impact, application areas, and reach of the OSP software as well as the relationships and collaboration patterns between organizations having published OSP-related articles between 2017 and 2023. Therefore, we conducted a bibliometric analysis of OSP-related publications and a social network analysis of the organizations with which authors of OSP-related publications were affiliated. On several levels, we found evidence for a significant growth in the size of the OSP community as well as its visibility in the MID3 community since OSP's establishment in 2017. Specifically, the annual publication rate of PubMed-indexed PBPK-related articles using the OSP software outpaced that of PBPK-related articles using any software. Our bibliometric analysis and network analysis demonstrated that the expansion of the OSP community was predominantly driven by new authors and organizations without prior connections to the community involving the generation of research clusters de novo and an overall diversification of the network. These findings suggest an ongoing evolution of the OSP community toward a more segmented, diverse, and inclusive network.
Collapse
Affiliation(s)
- André Dallmann
- Bayer HealthCare SAS, Loos, France
- Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany
| | - Donato Teutonico
- Translational Medicine & Early Development, Sanofi-Aventis R&D, Vitry-sur-Seine, France
| | | | - Rolf Burghaus
- Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany
| | - Sebastian Frechen
- Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany
| |
Collapse
|
3
|
Hamadeh A, Nash JF, Bialk H, Styczynski P, Troutman J, Edginton A. Mechanistic Skin Modeling of Plasma Concentrations of Sunscreen Active Ingredients Following Facial Application. J Pharm Sci 2024; 113:806-825. [PMID: 37769994 DOI: 10.1016/j.xphs.2023.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 09/19/2023] [Accepted: 09/20/2023] [Indexed: 10/03/2023]
Abstract
Sunscreen products constitute two distinct categories. Recreational sunscreens protect against high-intensity, episodic sun exposure, often applied over the entire body. In contrast, facial sunscreen products are designed for sub-erythemal, low-intensity daily sun exposure. Such different exposures necessitate distinctive product safety assessments. Building on earlier methods for predicting dermal disposition, a mechanistic model was developed to simulate plasma concentrations of seven organic sunscreen active ingredients: avobenzone, ensulizole, homosalate, octinoxate, octisalate, octocrylene, and oxybenzone, following facial application. In vitro permeation testing (IVPT) was performed with two different vehicles using a subset of the UV filters. These IVPT results, in addition to previously published IVPT data and published in vivo Maximal Usage Trial (MUsT) data for the UV filters, were used to train the mechanistic dermal model via a Bayesian Markov chain Monte Carlo (MCMC) method. An external validation of the trained model with real-world in vivo datasets demonstrated that the model's predicted UV filter plasma concentrations align well with experimental measurements and capture the observed inter-individual variability. Predictions of steady-state UV filter plasma concentrations under facial application scenarios at 5% concentration and at the maximal allowable concentrations were then generated by the trained model. Oxybenzone had the greatest predicted plasma concentration following facial application. Homosalate and octisalate predictions had high uncertainty associated with the absence of data. Several application scenarios pertaining to avobenzone, ensulizole, octocrylene and octinoxate were identified in which median plasma concentration levels were at 0.5 ng/ml or below when applied in the recreational or facial product. Model limitations include uncertainty in vehicle/water partitioning, formulation metamorphosis, and UV filter systemic clearance, all of which can be refined with additional data. For UV filters, limiting exposure to facial application reduces human safety concerns based on FDA established thresholds.
Collapse
Affiliation(s)
- Abdullah Hamadeh
- School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada; Systems In Silico Ltd., Waterloo, ON, Canada
| | - J F Nash
- The Procter & Gamble Company, Mason, OH 45040, USA
| | - Heidi Bialk
- The Estée Lauder Companies Inc., Melville, NY 11747, USA
| | | | | | - Andrea Edginton
- School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada; Design2Code Inc., Waterloo, ON, Canada.
| |
Collapse
|
4
|
Hamadeh A, Najjar A, Troutman J, Edginton A. Enhancement of Skin Permeability Prediction through PBPK Modeling, Bayesian Inference, and Experiment Design. Pharmaceutics 2023; 15:2667. [PMID: 38140008 PMCID: PMC10747907 DOI: 10.3390/pharmaceutics15122667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 11/14/2023] [Accepted: 11/18/2023] [Indexed: 12/24/2023] Open
Abstract
Physiologically based pharmacokinetic (PBPK) models of skin absorption are a powerful resource for estimating drug delivery and chemical risk of dermatological products. This paper presents a PBPK workflow for the quantification of the mechanistic determinants of skin permeability and the use of these quantities in the prediction of skin absorption in novel contexts. A state-of-the-art mechanistic model of dermal absorption was programmed into an open-source modeling framework. A sensitivity analysis was performed to identify the uncertain compound-specific, individual-specific, and site-specific model parameters that impact permeability. A Bayesian Markov Chain Monte Carlo algorithm was employed to derive distributions of these parameters given in vitro experimental permeability measurements. Extrapolations to novel contexts were generated by simulating the model following its update with samples drawn from the learned distributions as well as parameters that represent the intended scenario. This algorithm was applied multiple times, each using a unique set of permeability measurements sourced under experimental contexts that differ in terms of the compound, vehicle pH, skin sample anatomical site, and the number of compounds under which each subject's skin samples were tested. Among the data sets used in this study, the highest accuracy and precision in the extrapolated permeability was achieved in those that include measurements conducted under multiple vehicle pH levels and in which individual subjects' skin samples are tested under multiple compounds. This work thus identifies factors for consideration in the design of experiments for the purpose of training dermal models to robustly estimate drug delivery and chemical risk.
Collapse
Affiliation(s)
- Abdullah Hamadeh
- School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada;
- Systems In Silico Ltd., Waterloo, ON N2K 0B5, Canada
| | | | | | - Andrea Edginton
- School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada;
| |
Collapse
|
5
|
Tsakalozou E, Alam K, Ghosh P, Spires J, Polak S, Fang L, Sammeta S, Zhao P, Arora S, Raney SG. Mechanistic modeling of drug products applied to the skin: A workshop summary report. CPT Pharmacometrics Syst Pharmacol 2022; 12:575-584. [DOI: 10.1002/psp4.12893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Revised: 10/29/2022] [Accepted: 11/02/2022] [Indexed: 12/03/2022] Open
Affiliation(s)
- Eleftheria Tsakalozou
- Division of Quantitative Methods and Modeling Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) Silver Spring Maryland USA
| | - Khondoker Alam
- Division of Quantitative Methods and Modeling Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) Silver Spring Maryland USA
| | - Priyanka Ghosh
- Division of Therapeutic Performance I Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) Silver Spring Maryland USA
| | | | - Sebastian Polak
- Certara UK, Simcyp Division Sheffield UK
- Jagiellonian University Medical College Krakow Poland
| | - Lanyan Fang
- Division of Quantitative Methods and Modeling Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) Silver Spring Maryland USA
| | | | - Ping Zhao
- Bill & Melinda Gates Foundation Seattle Washington USA
| | - Sumit Arora
- Certara UK, Simcyp Division Sheffield UK
- Janssen Pharmaceutical, Companies of Johnson & Johnson Beerse Belgium
| | - Sam G. Raney
- Division of Therapeutic Performance I Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) Silver Spring Maryland USA
| |
Collapse
|